Lumonus, the digital oncology platform spun out of cancer services provider GenesisCare, and chaired by former Anchorage Capital Group boss Merrick Howes, has inked a joint venture agreement with a leading cancer treatment centre in New York.
The partnership will see Lumonus license and co-develop Memorial Sloan Kettering Cancer Center’s ECHO mathematical optimisation engine to further advance the automated radiation therapy treatment plans and workflow tools used by its oncologists.
Lumonus has two flagship products: Physician, an automated assistant helping practitioners summarise consultation data, organise documents, and review patient data, and Dosimetry, a platform where professionals can plan and coordinate oncology care.
Its pitch is that these tools can help specialists focus on delivering patient care while reducing administrative burdens. As of last November, the firm claimed to have facilitated circa 75,000 treatment plans across Australia, Europe and the United States.
“Together with MSK, we are building the infrastructure to move automation from promising results to scaled, routine deployment,” Lumonus chief product officer Tim Fox said on Wednesday.
